Investment Analysts’ Recent Ratings Changes for Electra Therapeutics (ETRA)

Electra Therapeutics (NASDAQ: ETRA) has recently received a number of price target changes and ratings updates:

• 10/13/2026 – Electra Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $32.00 price target on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $36.00 price target on the stock.
• 10/13/2026 – Electra Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 10/13/2026 – Electra Therapeutics was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 10/13/2026 – Electra Therapeutics was upgraded by Evercore Inc to “strong-buy”.
• 9/26/2026 – Electra Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Activity

In other news, Director Carl L. Gordon acquired 1,333,333 shares of Electra Therapeutics stock in a transaction dated Monday, September 21st. The stock was bought at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc acquired 1,333,333 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were purchased at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the acquisition, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This represents a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing.

Get Electra Therapeutics Inc alerts:

Electra Therapeutics, Inc is a clinical-stage biopharmaceutical company developing therapies for severe immune-mediated diseases. The company is focused on creating treatments designed to selectively remove disease-causing immune cells while preserving healthy immune cells.

Electra’s lead product candidate, ELA026, is an investigational antibody being developed for conditions involving harmful immune-cell activity. The company is evaluating the candidate in clinical studies for diseases including systemic sclerosis and immune thrombocytopenia.

Electra Therapeutics is headquartered in the United States and is focused primarily on advancing its pipeline through clinical development.

Read More

• Five stocks we like better than Electra Therapeutics
• Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway

Receive News & Ratings for Electra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.